SEC Form 4Coverage since Jun 1, 2026
$CTNM insider trading
Over the last 12 months, Contineum Therapeutics insiders reported no purchases and 7 sales totaling $1.1M across SEC Form 4 filings. 100% of the activity was filed under pre-arranged 10b5-1 trading plans.
- Bought · 12m
- — 0 events
- Sold · 12m
- $1.1M 7 events
- Events · 12m
- 7 Form 4 filings, grouped
- Insiders · 12m
- 3 distinct reporters
- 10b5-1 share
- 100% pre-arranged plans
Side
Price · $CTNM · 12Mvia TradingView
Top insiders · 12m
Stengone Carmine N.CEO and President3× · $240K
Lorrain Daniel S.Chief Scientific Officer3× · $666K
Watkins TimCMO & Head of Development1× · $174K
All insider trades
7 events
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Aug 3, 2026 | Stengone Carmine N.CEO and President · O·D | ▼ Sale | 2,500 | $16.01 | $40K | -12.7% | plan |
| Jul 9, 2026 | Lorrain Daniel S.Chief Scientific Officer · O | ▼ Sale | 1,040 | $16 | $17K | -0.8% | plan · 2 tranches |
| Jul 8, 2026 | Stengone Carmine N.CEO and President · O·D | ▼ Sale | 2,500 | $16 | $40K | -12.7% | plan |
| Jul 1, 2026 | Lorrain Daniel S.Chief Scientific Officer · O | ▼ Sale | 37,179 | $15.99 | $595K | -21.6% | plan · 3 tranches |
| Jun 30, 2026 | Watkins TimCMO & Head of Development · O | ▼ Sale | 10,833 | $16.02 | $174K | -54.7% | plan |
| Jun 30, 2026 | Stengone Carmine N.CEO and President · O·D | ▼ Sale | 10,000 | $16.01 | $160K | -36.7% | plan |
| Jun 1, 2026 | Lorrain Daniel S.Chief Scientific Officer · O | ▼ Sale | 4,170 | $13.16 | $55K | -2.9% | plan |
About Form 4
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $CTNM feed.